Skip to Content
Merck
CN
  • Frequency and characteristics of intraocular inflammation after aflibercept injection.

Frequency and characteristics of intraocular inflammation after aflibercept injection.

Retina (Philadelphia, Pa.) (2014-11-14)
Howard F Fine, Daniel B Roth, Sumit P Shah, Tahia Haque, H Matthew Wheatley
ABSTRACT

To report the frequency and characteristics of intraocular inflammation after intravitreal aflibercept injection. A single-center retrospective study was performed in patients who received intravitreal aflibercept from November 2011 through June 2013. There were 28 cases of intraocular inflammation after a total of 5,905 aflibercept injections among 1,660 patients. The mean baseline acuity was 20/57, which decreased to 20/179 at diagnosis (P < 0.0001) but recovered to 20/59 at Month 1, 20/57 at Month 3, and 20/52 at Month 6 (P = not significant). Vitreous culture and injection of antibiotics were performed in eight cases, and all were culture negative; the remainder received only topical corticosteroids. The frequency of inflammation after aflibercept was 0.47% per injection. Visual acuity and inflammation returned to baseline within 1 month in most cases with topical corticosteroid treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Iodine, anhydrous, beads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
Iodine, ≥99.99% trace metals basis
Sigma-Aldrich
Iodine, ReagentPlus®, 99.7% trace metals basis, beads, 1-3 mm
Sigma-Aldrich
Iodine, puriss., ≥99.5% (RT), particles (round)
Sigma-Aldrich
Iodine, 99.999% trace metals basis
Sigma-Aldrich
Iodine, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.8-100.5%
Sigma-Aldrich
Iodine, ACS reagent, ≥99.8%, solid
Supelco
Iodine, ReagentPlus®, ≥99.8% (titration)
Sigma-Aldrich
Iodine, flakes, ReagentPlus®, ≥99%